With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market VANCOUVER, April 25, 2017 /PRNewswire/ - RepliCel Life ...
VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈